Dermatology

Prof Reich welcomed delegates to the satellite symposium and explained that the aims of the meeting were to introduce the clinical role of targeted…

Registries provide very high-quality data on the persistence of different therapies in the real world and can be used to compare and guide therapeutic…

The satellite symposium comprised two short presentations aimed at providing an overview of the rationale for the use of interleukin (IL)-23 inhibition…

Prof Girolomoni provided an overview of psoriasis, considering how patients are frequently affected by other comorbidities.

The oral session consisted of a talk on the 2-year efficacy and safety of guselkumab in the treatment of moderate-to-severe psoriasis from the Phase III VOYAGE 1 trial.

Prof Costanzo welcomed attendees to the symposium and outlined the agenda before explaining the autoimmune pathophysiology that underlies psoriasis.

This symposium is focused on topical therapies in the treatment of psoriasis and the unmet clinical and patient quality of life needs.

Dermatologists today have more tools than ever at their disposal for managing psoriasis, including newer-generation biologics, which target molecular…